What is ESGCD?
ESCMID Study Group for Clostridioides difficile (ESGCD) is a group of clinicians and scientists from many European countries and further afield, who share an enthusiasm for Clostridioides difficile. We currently have more than 100 members.

What does ESGCD do?
At each ECCMID, a meeting is held where activities are planned. Funded research projects include surveillance of Clostridioides difficile at European level. We develop European guidelines on prevention, diagnosis and treatment of Clostridioides difficile infection and organise symposia at locations across Europe.

All are welcome!
Become a Member of the Study Group via the ESCMID website. Click on the Clostridioides difficile Study Group & follow the easy steps.

Important News
7th ICDS - International Clostridium difficile Symposium in Bled (Slovenia) is rescheduled to September 2022.

Recent ESGCD Publications

Recent ESGCD educational activities
- ICOHAR – International conference on One Health Antimicrobial Resistance (04/2019), Utrecht, The Netherlands
- ECDC Clostridioides difficile Infection Network Meeting (05/2019)
- ClostPath-International Conference on the Molecular Biology and Pathogenesis of the Clostridia (08/2019), Leiden, The Netherlands
- ICPIP: International Conference on Prevention and Infection Control, (09/2019), Geneva, Switzerland
- SHEA/CDC Decennial Meeting: Inside Out and Back Again: Healthcare-Associated MDROs in the Community (03/2020)

What is CDI?
Clostridium difficile infection (CDI) is a healthcare-associated infection caused by the bacterium Clostridium difficile, which can cause severe gastrointestinal symptoms and contribute to long-term morbidity and mortality.

Important News
- ECDC has coordinated CDI incidence surveillance in acute care hospitals (ACH) since January 2016. Over 21% of the ACHs in 23 EU/EEA countries have participated, with surveillance periods of 1-12 months each year. The 2020 update of the ECDC protocol for European surveillance of CDI includes several structure and process indicators of CDI prevention and control in accordance with the ESGCD Guidance document for prevention of CDI in acute healthcare settings. ACHs that do not already participate may wish to do so during a period designated for enhanced ACH participation, from 1 October to 31 December 2020.

Important News
- A new wave of the ECDC surveillance of Clostridium (Clostridioides) difficile infection (CDI) in Europe 1 October to 31 December 2020.

Recent ESGCD educational activities
- ICOHAR – International conference on One Health Antimicrobial Resistance (04/2019), Utrecht, The Netherlands
- ECDC Clostridioides difficile Infection Network Meeting (05/2019)
- ClostPath-International Conference on the Molecular Biology and Pathogenesis of the Clostridia (08/2019), Leiden, The Netherlands
- ICPIP: International Conference on Prevention and Infection Control, (09/2019), Geneva, Switzerland
- SHEA/CDC Decennial Meeting: Inside Out and Back Again: Healthcare-Associated MDROs in the Community (03/2020)

Sarah Tschudin Sutter
Karen Burns
Marcela Kurtova
Chairman: Prof. Sarah Tschudin Sutter, MD, MSc., Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Switzerland
Secretary: MSc. Marcela Krutova, Ph.D., Charles University/ Motol University Hospital Prague, Czech Republic
Treasurer: Karen Burns, MB MSc., Beaumont Hospital Dublin, Ireland.
On behalf of ESGCD

Dear colleagues, friends, and ESGCD study group members.
As you are aware, unfortunately, we will not have the opportunity to see each other at 30th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Paris. In this poster, we summarized the work that was done by ESGCD executive committee and the study group members in 2019 and we also highlight important news for 2020.

We wish you success in the fight against COVID-19 and whole-heartedly look forward to meeting you all in Vienna at ECCMID 2021!